PET Imaging of PARP with with [18F]olaparib".


Anna Pacelli, University of Oxford

Date & Time:

Tuesday, 20 November 2018, 13:30

Old Road Campus Research Building, Room 71a, b & c, Headington OX3 7DQ
CRUK & EPSRC Cancer Imaging Centre in Oxford

Poly (ADP‐ribose) polymerase (PARP) inhibitors are increasingly being studied as cancer drugs, as single agents or as a part of combination therapies. Imaging of PARP using a radiolabeled inhibitor has been proposed for patient selection, outcome prediction, and dose optimization of novel PARP‐targeting agents.
We have synthesised the fluorine-18 radiolabelled version of olaparib, an FDA-approved PARP inhibitor, and tested it in vitro and in vivo with promising results, and are now moving the first steps towards the clinical evaluation of this novel imaging agent.

About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.